News|Articles|February 3, 2024

Spotlighting Women on Our Editorial Advisory Board In Celebration of Women Physicians Day

Today is Women Physicians Day. We are celebrating women on our board who make positive strides in dermatology and strive to advance patient care.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related to this article

October 28th, 2026

Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.

October 27th, 2026

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

October 27th, 2026

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.

October 27th, 2026

ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.

October 26th, 2026

LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.

October 26th, 2026

ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.

October 25th, 2026

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

October 24th, 2026

Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.